

8. Dutta D et al. Occurrence & predictors of osteoporosis & impact of body composition alterations on bone mineral health in asymptomatic pre-menopausal women with HIV infection. *The Indian journal of medical research*, 2018; 147(5): p. 484–495.
9. Cairoli E et al. Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. *Osteoporos Int*, 2019; 30(6): p. 1255–1263.
10. Martínez-Morillo MD, Grados, and S. Holgado, Premenopausal Osteoporosis: How to Treat? *Reumatología Clínica (English Edition)*, 2012; 8(2): p. 93–97.
11. Weaver CM et al. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. *Osteoporos Int*, 2016; 27(4): p. 1281–1386.
12. Schousboe JT et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. *J Clin Densitom*, 2013; 16(4): p. 455–466.
13. Shepherd JA et al. Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD. *J Clin Densitom*, 2015; 18(3): p. 274–286.
14. Greendale GA et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). *J Bone Miner Res*, 2012; 27(1): p. 111–118.
15. Ferrari S et al. Osteoporosis in young adults: pathophysiology, diagnosis, and management. *Osteoporos Int*, 2012; 23(12): p. 2735–2748.
16. Lewiecki EM et al. Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases. *Journal of Clinical Densitometry*, 2017; 20(2): p. 134–152.
17. Lewiecki EM et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. *Bone*, 2008; 43(6): p. 1115–1121.
18. Buckley L et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis Rheumatol*, 2017; 69(8): p. 1521–1537.
19. Ferrari SL et al. Childhood fractures are associated with decreased bone mass gain during puberty: an early marker of persistent bone fragility? *J Bone Miner Res*, 2006; 21(4): p. 501–507.
20. Greendale GA et al. Premenopausal and early postmenopausal trabecular bone score (TBS) and fracture risk: Study of Women's Health Across the Nation (SWAN). *Bone*, 2020; 140: p. 115543.
21. Kužma M et al. High Serum Fractalkine is Associated with Lower Trabecular Bone Score in Premenopausal Women with Graves' Disease. *Horm Metab Res*, 2018; 50(8): p. 609–614.
22. Jackuliak P et al. Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. *Physiol Res*, 2019; 68(Suppl 2): p. S149–S156.
23. Ross AC et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol M et al. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol*, 1993; 121(2): p. 217–223.
25. Sokal A et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. *Osteoporos Int*, 2019; 30(1): p. 221–229.
26. Cohen A, Shane E. Evaluation and management of the premenopausal woman with low BMD. *Current osteoporosis reports*, 2013; 11(4): p. 276–285.
27. Fink HA et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. *Ann Intern Med*, 2019; 171(1): p. 37–50.
28. Wotton CJ et al. Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women. *Bone*, 2019; 124: p. 69–74.
29. Wood J et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. *J Pharmacol Exp Ther*, 2002; 302(3): p. 1055–1061.
30. Taxel P et al. Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. *Journal of the Endocrine Society*, 2018; 2(7): p. 574–588.
31. Gnant M et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. *Lancet Oncol*, 2011; 12(7): p. 631–641.
32. Hershman DL et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. *J Clin Endocrinol Metab*, 2010; 95(2): p. 559–566.
33. Delmas PD et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. *J Clin Oncol*, 1997; 15(3): p. 955–962.
34. Hines SL et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. *J Clin Oncol*, 2009; 27(7): p. 1047–1053.
35. Bone HG et al. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. *The Journal of Clinical Endocrinology & Metabolism*, 2008; 93(6): p. 2149–2157.
36. Finkelstein JS et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34): a randomized controlled trial. *Jama*, 1998; 280(12): p. 1067–1073.
37. Cohen A et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. *J Clin Endocrinol Metab*, 2013; 98(5): p. 1971–1981.
38. Choe EY et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. *J Bone Miner Metab*, 2012; 30(5): p. 596–601.
39. Langdahl BL et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. *Osteoporos Int*, 2009; 20(12): p. 2095–2104.
40. Curtis JR et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. *Arthritis Rheum*, 2006; 55(3): p. 420–426.
41. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? *Nat Rev Rheumatol*, 2015; 11(2): p. 98–109.
42. Payer J, Brazdilova K, Jackuliak P. Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. *Drug Healthc Patient Saf*, 2010; 2: p. 49–59.
43. Van Staa TP et al. Use of oral corticosteroids and risk of fractures. *J Bone Miner Res*, 2000; 15(6): p. 993–1000.
44. Miller KK et al. Determinants of skeletal loss and recovery in anorexia nervosa. *J Clin Endocrinol Metab*, 2006; 91(8): p. 2931–2937.
45. Tichá L et al. Porucha kostného metabolizmu pri mentálnej anorexii. *Čes-slov Pediat*, 2016; 71(5–6): p. 287–292.
46. Sim LA et al. Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses. *Int J Eat Disord*, 2010; 43(3): p. 218–225.
47. Baqi L et al. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women. *Endocr Regul*, 2010; 44(2): p. 57–63.
48. Kuzma M, Payer J. (Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures). *Cas Lek Cesk*, 2010; 149(5): p. 211–216.
49. Kužma M et al. (Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood). *Vnitr Lek*, 2017; 63(10): p. 658–661.
50. Kužma M et al. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. *Growth Horm IGF Res*, 2014; 24(1): p. 22–28.
51. Kužma M et al. Kvalita kosti u akromegalikov. *Vnitřní lékařství*, 2017; 63(9): p. 589–592.
52. Kužma M et al. Trabecular Bone Score Change Differs with Regard to 25(OH)D Levels in Patients Treated for Adult-Onset Growth Hormone Deficiency. *Endocrine Practice*, 2016; 22(8): p. 951–958.
53. Kužma M et al. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. *Eur J Endocrinol*, 2019; 180(3): p. 201–211.
54. World Health, O., Guideline: calcium supplementation in pregnant women. 2013, Geneva: World Health Organization.
55. Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, 2011; 96(7): p. 1911–1930.
56. Kalkwarf HJ et al. The effect of calcium supplementation on bone density during lactation and after weaning. *N Engl J Med*, 1997; 337(8): p. 523–528.
57. Scioscia MF et al. Severe Bone Microarchitecture Impairment in Women With Pregnancy and Lactation-Associated Osteoporosis. *J Endocr Soc*, 2021; 5(5): p. bvab031.
58. O'Sullivan SM et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis. *Osteoporos Int*, 2006; 17(7): p. 1008–1012.
59. Cerit ET, Cerit M. A case of pregnancy and lactation associated osteoporosis in the third pregnancy; robust response to teriparatide despite delayed administration. *Bone reports*, 2020; 13: p. 100706–100706.
60. Recker RR et al. Bone gain in young adult women. *Jama*, 1992; 268(17): p. 2403–2408.
61. Peris P et al. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. *Clin Rheumatol*, 2007; 26(6): p. 958–961.